CenterBook Partners LP Buys Shares of 811,926 Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)

CenterBook Partners LP bought a new position in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 811,926 shares of the company's stock, valued at approximately $4,425,000. CenterBook Partners LP owned about 0.32% of Maravai LifeSciences at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the business. Charles Schwab Investment Management Inc. grew its holdings in shares of Maravai LifeSciences by 6.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 946,576 shares of the company's stock worth $7,866,000 after acquiring an additional 56,071 shares during the period. The Manufacturers Life Insurance Company grew its stake in Maravai LifeSciences by 36.0% in the third quarter. The Manufacturers Life Insurance Company now owns 58,987 shares of the company's stock worth $490,000 after purchasing an additional 15,615 shares during the period. XTX Topco Ltd purchased a new stake in Maravai LifeSciences in the third quarter worth $193,000. Orion Portfolio Solutions LLC lifted its position in Maravai LifeSciences by 4.8% during the third quarter. Orion Portfolio Solutions LLC now owns 135,749 shares of the company's stock valued at $1,128,000 after buying an additional 6,177 shares during the period. Finally, Y Intercept Hong Kong Ltd bought a new stake in shares of Maravai LifeSciences during the 3rd quarter valued at $105,000. Hedge funds and other institutional investors own 50.25% of the company's stock.

Analyst Upgrades and Downgrades

MRVI has been the subject of a number of recent research reports. Guggenheim initiated coverage on shares of Maravai LifeSciences in a research report on Thursday, December 19th. They set a "neutral" rating for the company. Baird R W lowered Maravai LifeSciences from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, February 26th. UBS Group cut their price objective on shares of Maravai LifeSciences from $8.00 to $2.50 and set a "neutral" rating on the stock in a research report on Friday, March 21st. Bank of America cut their price target on shares of Maravai LifeSciences from $9.00 to $8.00 and set a "buy" rating on the stock in a report on Monday, March 3rd. Finally, Morgan Stanley reduced their price target on shares of Maravai LifeSciences from $7.00 to $5.00 and set an "equal weight" rating for the company in a research report on Tuesday, March 25th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have given a buy rating to the stock. According to MarketBeat, Maravai LifeSciences has a consensus rating of "Hold" and a consensus target price of $6.34.

Remove Ads

Maravai LifeSciences Trading Down 4.5 %

NASDAQ MRVI traded down $0.08 on Tuesday, hitting $1.69. 1,231,187 shares of the stock were exchanged, compared to its average volume of 2,347,918. The firm has a market capitalization of $429.83 million, a P/E ratio of -1.03 and a beta of 0.18. Maravai LifeSciences Holdings, Inc. has a 52-week low of $1.69 and a 52-week high of $11.56. The stock has a fifty day moving average price of $2.89 and a two-hundred day moving average price of $4.98. The company has a debt-to-equity ratio of 0.89, a quick ratio of 9.94 and a current ratio of 10.74.

Insider Buying and Selling

In other news, General Counsel Kurt Oreshack sold 25,000 shares of the business's stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $5.03, for a total value of $125,750.00. Following the completion of the sale, the general counsel now owns 167,618 shares in the company, valued at approximately $843,118.54. The trade was a 12.98 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.63% of the stock is owned by insiders.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.